Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. info@dimerix.com For Immediate Release DIMERIX ANNOUNCES BOARD CHAIR TRANSITION MELBOURNE, Australia, 19...
Dimerix Announces Board Chair Transition
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
- Dimerix at Canaccord Drug & Device and Ignite Conferences
- First Patient Reaches Four Years in DMX-200 Clinical Program
- Notification regarding unquoted securities - DXB
- Notification of 2026 Annual General Meeting Date
Later from Dimerix
- 2026 AGM Notice of Meeting, Letter of Access and Proxy Form
- New Data Supports Biological Rationale for DMX-200 in FSGS
- Dimerix Quarterly Activities Report and Appendix 4C
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix